data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

My Account

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Freight
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Humacyte Inc

(NASDAQ:HUMA)

$2.82

0[0.00%]

Last update: 7:46PM (Delayed 15-Minutes)
Get Real Time Here

$2.82

0[0.00%]

Open2.800	Close2.750
Vol / Avg.312.936K / 665.038K	Mkt Cap291.685M
Day Range2.700 - 2.812	52 Wk Range1.960 - 5.600

0

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Latest News for Humacyte Stock (NASDAQ:HUMA)

Humacyte Stock (NASDAQ: HUMA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, September 21, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Benzinga Newsdesk - Sep 21, 2023, 9:04AM

Tuesday, September 12, 2023

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Vandana Singh - Sep 12, 2023, 2:31PM
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Sep 12, 2023, 1:44PM
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Sep 12, 2023, 8:00AM
Humacyte Announced Topline Results From V005 Phase 2/3 Trial Of Human Acellular Vessel (HAV) In Vascular Trauma Repair, Showing That HAV Had Higher Rates Of Patency, Lower Rates Of Amputation And Infection, Compared To Historic Synthetic Graft Benchmarks
Benzinga Newsdesk - Sep 12, 2023, 7:05AM

Monday, September 11, 2023

Results From Mayo Clinic Clinical Study Of Humacyte's Human Acellular Vessel For Chronic Limb Ischemia Presented At Midwestern Vascular Conference
Benzinga Newsdesk - Sep 11, 2023, 8:11AM

Thursday, August 31, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 31, 2023, 10:17AM

Thursday, August 24, 2023

Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $6 Price Target
Benzinga Newsdesk - Aug 24, 2023, 10:33AM

Tuesday, August 22, 2023

Massive Insider Trade At Humacyte
Benzinga Insights - Aug 22, 2023, 11:02AM
Humacyte Insider Trades Send a Signal
Benzinga Insights - Aug 22, 2023, 11:02AM
10% Owner of Humacyte Makes $6.38M Sale
Benzinga Insights - Aug 22, 2023, 11:02AM

Wednesday, August 16, 2023

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
Chris Katje - Aug 16, 2023, 3:53PM

Tuesday, August 15, 2023

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 15, 2023, 10:42AM
Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Aug 15, 2023, 9:56AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Aug 14, 2023, 1:31PM
Humacyte shares are trading higher after the company reported Q2 financial results.
Benzinga Newsdesk - Aug 14, 2023, 12:04PM
Humacyte Q2 EPS $(0.22), Inline
Benzinga Newsdesk - Aug 14, 2023, 7:03AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Humacyte Earnings Preview
Benzinga Insights - Aug 11, 2023, 10:01AM

Thursday, August 03, 2023

Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel
Benzinga Newsdesk - Aug 3, 2023, 8:15AM

Wednesday, July 26, 2023

Humacyte Completes Enrollment In Phase 2/3 Trial Of Human Acellular Vessel For Vascular Trauma Repair
Bill Haddad - Jul 26, 2023, 8:03AM

Thursday, June 22, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Benzinga Insights - Jun 22, 2023, 11:02AM
Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 22, 2023, 9:07AM

Monday, June 12, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Jun 12, 2023, 7:40AM

Wednesday, May 24, 2023

Humacyte-Sponsored An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma Posted To ClinicalTrials.gov
Charles Gross - May 24, 2023, 10:37AM

Friday, May 12, 2023

Humancyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Benzinga Newsdesk - May 12, 2023, 11:42AM
Earnings Scheduled For May 12, 2023
Benzinga Insights - May 12, 2023, 8:22AM
Recap: Humacyte Q1 Earnings
Benzinga Insights - May 12, 2023, 7:15AM
Humacyte Q1 EPS $(0.36) Misses $(0.21) Estimate; Cash, Cash Equivalents And Short-Term Investments $131.7M
Benzinga Newsdesk - May 12, 2023, 7:07AM
Humacyte And Oberland Capital Management Announced A $150M, Capped Funding Arrangement Based On Future Revenues Of Humacyte's Human Acellular Vessel, As Well As A $10M Equity Investment Option
Benzinga Newsdesk - May 12, 2023, 7:05AM

Thursday, May 11, 2023

Earnings Outlook For Humacyte
Benzinga Insights - May 11, 2023, 10:01AM

Monday, May 08, 2023

Six Flags Entertainment, Zscaler, Energizer And Other Big Stocks Moving Higher On Monday
Lisa Levin - May 8, 2023, 10:40AM

Thursday, May 04, 2023

Humacyte's Human Acellular Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Urgent Arterial Repair Following Vascular Trauma
Happy Mohamed - May 4, 2023, 8:19AM

Tuesday, May 02, 2023

Watching Humacyte, VolitionRX; Hearing Banyan Hills Newsletter Buys Stock
Benzinga Newsdesk - May 2, 2023, 12:35PM

Tuesday, April 18, 2023

Humacyte Publishes Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Benzinga Newsdesk - Apr 18, 2023, 8:07AM

Tuesday, April 11, 2023

Humacyte Completes Enrollment In Phase 3 Trial Of Human Acellular Vessel For Hemodialysis Access In End-Stage Renal Disease Patients
Benzinga Newsdesk - Apr 11, 2023, 8:11AM

Monday, March 27, 2023

Benchmark Reiterates Buy on Humacyte, Maintains $16 Price Target
Benzinga Newsdesk - Mar 27, 2023, 7:29AM

Friday, March 24, 2023

Earnings Scheduled For March 24, 2023
Benzinga Insights - Mar 24, 2023, 9:19AM
Humacyte Q4 EPS $(0.04) Beats $(0.23) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $151.9M Expected To Provide Cash Runway Into End of 2024
Benzinga Newsdesk - Mar 24, 2023, 7:05AM

Thursday, March 23, 2023

Earnings Preview For Humacyte
Benzinga Insights - Mar 23, 2023, 10:01AM

Monday, March 13, 2023

Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights - Mar 13, 2023, 10:43AM

Monday, February 13, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 13, 2023, 4:31PM
5 Value Stocks In The Healthcare Sector
Benzinga Insights - Feb 13, 2023, 9:43AM

Tuesday, January 24, 2023

Humacyte Publication In The Journal Of Vascular Surgery, Vascular Science Reports The Human Acellular Vessel Remains Durable At Six Years In Patients With Peripheral Artery Disease
Benzinga Newsdesk - Jan 24, 2023, 8:13AM

Monday, December 26, 2022

5 Value Stocks In The Healthcare Sector
Benzinga Insights - Dec 26, 2022, 9:43AM

Wednesday, December 21, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 21, 2022, 11:58AM

Monday, December 19, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Dec 19, 2022, 12:40PM
Humacyte's Return on Invested Capital Insights
Benzinga Insights - Dec 19, 2022, 9:49AM

Thursday, December 15, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Dec 15, 2022, 11:19AM

Wednesday, December 14, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Dec 14, 2022, 2:20PM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved